Humacyte Inc (HUMA) concluded trading on Wednesday at a closing price of $3.43, with 4.57 million shares of worth about $15.67 million changed hands on the day. Half year performance of the stock remained negative as price took a plunge of -51.21% during that period and on Wednesday the price saw a gain of about 12.83%. Currently the company’s common shares owned by public are about 119.84M shares, out of which, 104.39M shares are available for trading.
Stock saw a price change of -11.37% in past 5 days and over the past one month there was a price change of -23.95%. Year-to-date (YTD), HUMA shares are showing a performance of -32.08% which decreased to -20.79% when we look at its performance for past 12 months. Over the period of past 52 weeks, stock dropped to lowest price of $2.81 but also hit the highest price of $9.97 during that period. The average intraday trading volume for Humacyte Inc shares is 4.12 million. The stock is currently trading -14.01% below its 20-day simple moving average (SMA20), while that difference is down -20.80% for SMA50 and it goes to -38.98% lower than SMA200.
Humacyte Inc (NASDAQ: HUMA) currently have 119.84M outstanding shares and institutions hold larger chunk of about 33.11% of that.
The stock has a current market capitalization of $441.33M and its 3Y-monthly beta is at 1.38. It has posted earnings per share of -$1.34 in the same period. It has Quick Ratio of 1.10. Volatility of a stock is a metric used to know how much the price of that stock is under influence and for HUMA, volatility over the week remained 9.37% while standing at 6.47% over the month.
Stock’s fiscal year EPS is expected to drop by -26.79% while it is estimated to increase by 36.29% in next year.
Digging deeper we find that several firms have released their research notes about the support levels of the stock. Most recent of them is a note released by H.C. Wainwright on December 20, 2024 offering a Buy rating for the stock and assigned a target price range of between $12 and $15 to it. Coverage by H.C. Wainwright stated Humacyte Inc (HUMA) stock as a Buy in their note to investors on December 11, 2023, suggesting a price target of $6 for the stock. On August 14, 2023, Piper Sandler Upgrade their recommendations, while on June 22, 2023, Cantor Fitzgerald Initiated their ratings for the stock with a price target of $6. Stock get an Underweight rating from Piper Sandler on May 16, 2022.
